OncoMatch/Clinical Trials/NCT06637423
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Is NCT06637423 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Sacituzumab tirumotecan and Rescue medication for non-muscle invasive bladder cancer.
Treatment: Sacituzumab tirumotecan · Rescue medication · Supportive care measures — The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Excluded: Stage CIS
Grade: low
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Michael G Oefelein Clinical Trials ( Site 0053) · Bakersfield, California
- Moffitt Cancer Center ( Site 0057) · Tampa, Florida
- Northwestern University ( Site 0051) · Chicago, Illinois
- Johns Hopkins University ( Site 0055) · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify